Recent work | December 20, 2023

Roschier represented TA Associates as principal shareholder in the fully underwritten SEK 4.3 billion rights issue in Elos Medtech

Roschier has advised TA Associates ("TA") in the SEK 4.3 billion rights issue in Elos Medtech. The rights issue was fully underwritten by the principal shareholder TA, through EM Intressenter.

As a result of the fully subscribed rights issue, TA, through EM Intressenter, controls more than 90 percent of the shares in Elos Medtech and has initiated a compulsory redemption of the remaining shares in the company and requested that the shares in Elos Medtech shall be de-listed from Nasdaq Stockholm. The last day of trading in Elos Medtech’s shares occurred on 19 December 2023.

TA is a leading global private equity firm focused on scaling growth in profitable companies.

Elos Medtech is a development and production partner for medical devices and components, with a focus on dental and orthopedic implants and instruments. The company operates from facilities in Sweden, Denmark, China and the U.S.

Roschier’s core advisory team comprised Ola Sandersson, Erik Persson, Pontus Berganäs, Sazan Anwar, Veronica Stiller, Andrew Laderman, Marcus Kern Fahlander, Sofia Moberg, Leo Lee and Fredrik Eriksson Oppliger.